Скачать с ютуб Q14. What are the key points of the US ASA 2023 guidelines on management of neuromuscular blockade? в хорошем качестве

Q14. What are the key points of the US ASA 2023 guidelines on management of neuromuscular blockade?

In this compelling excerpt from Dr. Cammu's recent presentation, we journey through the newly introduced guidelines in the United States concerning anesthesiology practices as of early 2023. These guidelines, published in "Anesthesiology", echo to some extent the European Society's recommendations but with distinct nuances. Dr. Cammu emphasizes the U.S.'s strict stance against relying solely on clinical assessment for neuromuscular blockade, advocating instead for quantitative over qualitative monitoring to evade potential residual neuromuscular blockades. With each recommendation, he delves into the specifics, including the notable directive against using eye muscles for neuromuscular monitoring, the conditional usage of neostigmine, and the insights on clinical care practices worldwide, particularly highlighting Japan's extensive use of sugammadex. The segment closes with an eye-opening study by Japanese anesthetist Kotake, underscoring the undeniable importance of precise neuromuscular transmission monitoring, regardless of the antagonistic agent used. Want to grasp the full depth of these evolving guidelines and their implications? Explore the complete webinar   • Insights from Neuromuscular Block Mon...  . For continuous updates and medical expertise, don't forget to subscribe to our channel.